Amgen Buys Dezima For Up To $1.55 Billion

Thousand Oaks-based Amgen announced this morning that it is in a deal to acquire Netherlands-based Dezima Pharma B.V., in a deal worth up to $1.55 billion. Dezima Pharma is a biotechnology company developing cholesterol-lowering drugs. Amgen said it will pay $300M in cash at closing, and up to $1.25 billion in additional payments based on development and sales milestones for Dezima. Dezima's products are in Phase 2b trails, and are used for reducing low-density lipoprotein cholesterol (LDL-C) in the bloodstream.